Novo inks $1.33bn long-lasting injectable pact with Sweden-based Nanexa

PartnershipPositive

AI Analysis

Summary

Novo has entered a $1.33 billion partnership with Sweden-based Nanexa to develop long-lasting injectable therapeutics, supporting Novo's objective to launch over five multi-blockbuster drugs by 2030.

Importance:7/10

Sentiment:

0.60

partnershiplicensinginjectablelong-actingpipeline_expansion

Related Companies

$CBDY

Read the original article

Published by Pharmaceutical Technology on September 28, 2026 9:34 AM

Read Original